Related Experiment Videos
An update on renovascular hypertension.
Martin Senitko1, Andrew Z Fenves
1Nephrology Division, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA.
Current Cardiology Reports
|November 1, 2005
Summary
Renovascular hypertension (RVH) is a secondary high blood pressure caused by kidney artery narrowing. Treatment focuses on improving blood flow to the kidneys, but optimal therapy for atherosclerotic renal artery stenosis remains debated.
Area of Science:
- Nephrology
- Cardiology
- Vascular Surgery
Background:
- Renovascular hypertension (RVH) is a secondary, treatable cause of elevated blood pressure.
- Decreased renal perfusion leads to various pathophysiologic consequences beyond hypertension.
- Advances in noninvasive detection of renal artery stenosis are improving, yet functional assessment remains limited.
Purpose of the Study:
- To review the disease mechanisms, clinical findings, and therapeutic strategies for RVH.
- To discuss evolving trends and developments in managing RVH.
- To focus on atherosclerotic renal artery stenosis (ARAS) and fibromuscular dysplasia as primary causes of RVH.
Main Methods:
- Review of current literature on renovascular hypertension.
- Discussion of diagnostic and therapeutic approaches for ARAS and fibromuscular dysplasia.
- Analysis of endovascular techniques and their impact on renal function.
Main Results:
- Atherosclerotic renal artery stenosis (ARAS) and fibromuscular dysplasia are the most common causes of RVH.
- Endovascular techniques offer potential for improving renal function in ischemic nephropathy.
- Consensus on the optimal therapy for ARAS is still lacking.
Conclusions:
- RVH is a significant condition requiring careful management.
- Further research is needed to establish consensus on the best therapeutic strategies for ARAS.
- Improved understanding of disease mechanisms and treatment efficacy is crucial for patient outcomes.